Results 131 to 140 of about 2,070,589 (168)

In Vitro Cytotoxicity and Inflammatory Response of Local Anaesthetics and Corticosteroids in Canine Fibroblast-Like Synoviocytes. [PDF]

Cartilage
Sousa C, Lima A, Belas A, Campos S.
europepmc   +1 more source

Efficacy and Safety of 0.5 mg Ranibizumab Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Central Retinal Vein Occlusion Over 6 Months: The COMRADE-C Study

, 2018
Hoerauf, Hans, Feltgen, Nicolas, Eter, Nicole, Hattenbach, Lars-Olof, Rehak, Matus, Pankaj, Puri, Berk, Huesnue, Knorr, Thomas   +7 more
openaire   +1 more source

Efficacy and Safety of 0.5 mg Ranibizumab Administered as Intravitreal Injections PRN Compared with Intravitreal Implant Containing 0.7 mg Dexamethasone in Patients with Branch Retinal Vein Occlusion Over 6 Months: The COMRADE-B Study

, 2018
Hattenbach, Lars-Olof, Hoerauf, Hans, Feltgen, Nicolas, Lang, Gabrielle, Taylor, Simon, Schmitz-Valckenberg, Steffen, Wolf, Armin, Knorr, Thomas   +7 more
openaire   +1 more source

Efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg in central retinal vein occlusion: 6-month results of the COMRADE-C study

, 2018
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A Comparison of Ocular Complications after 0.7 mg Dexamethasone Implant versus 2 mg of Intravitreal Triamcinolone in Vitrectomized Eyes

Ophthalmology Retina, 2023
To compare the rates of complications in eyes that received a dexamethasone (DEX) implant (0.7 mg) or intravitreal triamcinolone (IVT) (2 mg) to treat postvitrectomy macular edema (ME).Retrospective, comparative, case series.A total of 148 eyes (147 patients); 75 eyes (75 patients) in the DEX group and 73 eyes (72 patients) in the IVT group.The medical
Taku Wakabayashi, Catherine K. Liu, Hannah E. Anderson, Raziyeh Mahmoudzadeh, Michael K. Nguyen, Mirataollah Salabati, Allen Chiang, Jason Hsu, Sunir J. Garg, Marc J. Spirn   +9 more
openaire   +2 more sources

Ocular hypertension following 40 mg sub-Tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinolone

Canadian Journal of Ophthalmology, 2020
To compare rates of ocular hypertension (OHT) in eyes receiving 40 mg sub-Tenon triamcinolone (STT), 0.7 mg dexamethasone implant (DEX), and 2 mg intravitreal triamcinolone (IVT).This study is a single-centre, retrospective case series. All patients receiving STT and DEX between 4/1/2014 and 3/1/2017 and IVT between 3/1/2012 and 3/1/2017 with a minimum
Brandon Kuley, Philip P. Storey, Maitri Pancholy, Nicholas Bello, James Murphy, Jake Goodman, Turner D. Wibbelsman, Anthony Obeid, Allen Chiang, Carl Regillo, Sunir Garg   +10 more
openaire   +2 more sources

INTRAVITREAL DEXAMETHASONE 0.7-MG IMPLANT FOR RADIATION MACULAR EDEMA AFTER PROTON BEAM THERAPY FOR CHOROIDAL MELANOMA

Retina, 2013
To evaluate the efficacy of dexamethasone 0.7-mg intravitreal implant in patients with radiation macular edema after proton beam therapy for choroidal melanoma.Five patients' charts were retrospectively reviewed. The main outcome measures were visual acuity and mean central retinal thickness.All patients received a radiation dose of 60 cobalt gray ...
Stéphanie, Baillif, Celia, Maschi, Pierre, Gastaud, Jean Pierre, Caujolle   +3 more
openaire   +2 more sources

Treatment of Eyes With Diabetic Macular Edema That Had a Suboptimal Response to Antivascular Endothelial Growth Factor Therapy: 2-mg Intravitreal Triamcinolone Acetonide vs 0.7-mg Dexamethasone Implant

Journal of VitreoRetinal Diseases, 2020
Purpose: This article compares 2-mg intravitreal triamcinolone (IVT) and 0.7-mg dexamethasone (DEX) implant for the treatment of diabetic macular edema in eyes that had a suboptimal response to antivascular endothelial growth factor therapy. Methods:
Brandon Kuley, Philip P. Storey, Maitri Pancholy, Turner D. Wibbelsman, Anthony Obeid, Carl Regillo, Sunir Garg   +6 more
openaire   +2 more sources

Secondary Glaucoma After Intravitreal Dexamethasone 0.7 mg Implant in Patients with Retinal Vein Occlusion: A One-Year Follow-Up

Journal of Ocular Pharmacology and Therapeutics, 2013
Abstract Purpose: To investigate the rate of secondary glaucoma after intravitreal dexamethasone 0.7 mg (Ozurdex ® ) implantation over a clinical treatment period of 1 year.
Linda M, Meyer, Carl-Ludwig, Schönfeld
openaire   +2 more sources

Dexamethasone 0.7‐mg intravitreal implant in patients with radiation macular edema after proton beam therapy for choroidal melanoma: 2‐year results

Acta Ophthalmologica, 2015
PurposeTo evaluate over a 2‐year period, the efficacy of dexamethasone 0.7‐mg intravitreal implant in patients with radiation macular edema after proton beam therapy for choroidal melanoma.MethodsNine patients’ charts were retrospectively reviewed.
S. Baillif, C. Maschi, J.P. Caujolle
openaire   +1 more source